Exhaling a budesonide inhaler through the nose results in a significant reduction in dose requirement of budesonide nasal spray in patients having asthma with rhinitis

Journal of Investigational Allergology and Clinical Immunology

Volumn 9, Issue 1, 1999, Pages 45-49

  Shaikh, W A ^a,b  

^a BOMBAY HOSPITAL   (India)

^b Shakti Sadan Co op Housing Society   (India)

Author keywords

Asthma; Budenonide; Corticosteroid; Inhaler; Nasal spray; Rhinitis

Indexed keywords

ANTIASTHMATIC AGENT; BUDESONIDE;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; EXHALATION; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; METERED DOSE INHALER; PARALLEL DESIGN; RHINITIS;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADULT; ASTHMA; BUDESONIDE; CLINICAL TRIALS, PHASE III; CROSS-OVER STUDIES; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; MALE; METHODS; NEBULIZERS AND VAPORIZERS; PATIENT DROPOUTS; RHINITIS;

EID: 0033027376     PISSN: 10189068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Lewis, J. The Asthma Handbook. Vermillion: London 1995, 87.
2. Mirahian, P., Howarth, P., Scadding, G. New thinking on the treatment of rhinitis. The Practitioner 1997, 24: 286-290.
3. Hassard, T.H. Understanding Biostatistics. Mosby Year Book: St. Louis 1991, A-11.
4. Van Essen-Zandvliet, E.E.M., Hughes, M.D., Waalkens, H.J., Duiverman, E.J., Pocock, S.J., Kerrebijn, K.F., Dutch CNSLD Study Group. Effects of 22 months treatment with inhaled corticosteroid and/or beta-2 agonist on lung function, airway responsiveness and symptoms in children with asthma. Am Rev Resp Dis 1992, 146: 547-54.
5. Woolcock, A.J., Yan, K., Salome, C.M. Effect of therapy on bronchial hyperrresponsiveness in long term management of asthma. Clin Allergy 1988, 18 (2): 165-76.
6. Newman, S.P., Pavia, D., Moren, F., Sheahan, N.F., Clarke, S.W. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981, 36: 52-5.
7. Newman, S.P. Therapeutic aerosol deposition in man. In: Aerosols in Medicine: Principles, Diagnosis and Therapy. 2nd ed. Moren, R, Dolovich, M.B., Newhouse, M.T., Newman, S.P. (Eds.). Elsevier Science: Amsterdam 1993, 375-99.
8. Mygind, N., Dahl, R., Pedersen, S., Thestrup-Pedersen, K. Essential Allergy, 2nd ed. Blackwell Science: Oxford 1996, 300.
9. Lipworth, B.J. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995, 50: 105-10.
10. Newman, S.P., Moren, F., Clarke, S.W. Deposition pattern of nasal sprays in man. Rhinology 1987, 26: 110-20.
11. Newman, S.P., Moren, F., Clarke, S.W. The nasal distribution of metered-dose inhalers. J Laryngol Otol 1987, 101: 127-32.
12. Hochhaus, G., Mollman, H., Derendorf, H., Gonsalez-Rothi, R.J. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997, 37: 881-92.
13. Brattsand, R., Ingelf, J. Pharmacodynamic basis for inhaled glucocorticosteroid (GCS) therapy in allergic rhinitis. In: Respiratory Allergy: Advances in Clinical Immunology and Pulmonary Medicine. Melillo, G., O'Byrne, P.M., Marone, G. (Eds.). Elsevier BV: Amsterdam 1993, 129-36.